-
FDA approves Alembic’s generic drug for Major Depressive Disorder
- June 12, 2018
- Posted by: PharmaScroll
- Category:
No Comments -
Esketamine displays positive Ph 3 trial outcomes for Depression
- June 3, 2018
- Posted by: PharmaScroll
- Category:
-
Allergan acquires depression compound from Aptinyx
- May 24, 2018
- Posted by: PharmaScroll
- Category:
-
33 percent more people suffer from Depression as compared to 2013, new research finds
- May 11, 2018
- Posted by: PharmaScroll
- Category:
-
Esketamine improves outcomes in Treatment-Resistant Depression patients, new Phase 3 data shows
- May 8, 2018
- Posted by: PharmaScroll
- Category:
-
NDA submitted for Brexanolone in Postpartum Depression by Sage Therapeutics
- April 24, 2018
- Posted by: PharmaScroll
- Category:
-
Intranasal Esketamine improves Depression symptoms as per latest clinical trial results
- April 21, 2018
- Posted by: PharmaScroll
- Category: